Dexmethylphenidate

Drugs

Volumn 62, Issue 13, 2002, Pages 1899-1904

  Keating, Gillian M ^a   Figgitt, David P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DEXMETHYLPHENIDATE; METHYLPHENIDATE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANOREXIA; AREA UNDER THE CURVE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CLINICAL TRIAL; COUGHING; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INSOMNIA; MALE; NAUSEA; NIGHTMARE; PARENT; RATING SCALE; REVIEW; RHINITIS; SCHOOL CHILD; SCORING SYSTEM; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SYMPTOM; TEACHER; THORAX PAIN; TREATMENT FAILURE; TREATMENT INDICATION; URINARY EXCRETION;

EID: 0036385731     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262130-00009     Document Type: Review

References (15)

1. Brown RT, Freeman WS, Perrin JM, et al. Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics 2001 Mar; 107 (3): E43
2. Committee on Quality Improvement, Subcommittee on Attention-Deficity/Hyperactivity Disorder. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. American Academy of Pediatrics. Pediatrics 2000 May; 105 (5): 1158-70
3. Rappley MD. Safety issues in the use of methylphenidate: an American perspective. Drug Saf 1997 Sep; 17 (3): 143-8
4. Srinivas NR, Hubbard JW, Quinn D, et al. Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder. Clin Pharamcol Ther 1992 Nov; 52: 561-8
5. Novartis. Focalin™ dexmethylphenidate hydrochloride tablets: prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com [Accessed 2002 May 15]
6. Safer DJ. Central stimulant treatment of childhood attention deficit hyperactivity disorder: issues and recommendations from a US perspective. CNS Drugs 1997 Apr; 7 (4): 264-72
7. Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 1999 Dec; 6: 457-70
8. Findling RL, Dogin JW. Psychopharmacology of ADHD: children and adolescents. J Clin Psychiatry 1998; 59 Suppl. 7: 42-9
9. Patrick KS, Markowitz JS. Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder. Hum Psychopharmacol 1997 Nov-Dec; 31(12): 527-46
10. Spencer TJ, Biederman J, Harding J, et al. Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiatry 1996; 35: 1460-9
11. Conners CK, Casat C, Coury D, et al. Randomized trial of dexmethylphenidate hydrochloride (Focalin™) and racemic methylphenidate hydrochloride (d,l-MPH) in children with ADHD [abstract no. 345 and poster]. American Psychiatric Assocation 2002 Annual Meeting; 2002 May 18-23; Philadelphia (PA).
12. Celgene Corporation. Attenade™ (d-threo-Methylphenidate HCl) Tablets. Data on file. 2002
13. Novartis. Focalin™ product monograph. 2002
14. West SA, Johnson D, Wigal S, et al. A double-blind, randomized, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride (Focalin™) in children with symptoms of attention-deficit/hyperactivity disorder (ADHD) [abstract no. 341 and poster]. American Psychiatric Assocation 2002 Annual Meeting; 2002 May 18-23; Philadelphia (PA).
15. Silva R, Tilker H, Cecil Jr J, et al. Open-label pilot study of dexmethylphenidate in children with ADHD [abstract no. P19 and poster]. 48th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 2001 Oct 23-28; Honlulu (HI).